Edap Tms (NASDAQ:EDAP) Cut to “Sell” at StockNews.com

StockNews.com lowered shares of Edap Tms (NASDAQ:EDAP) from a hold rating to a sell rating in a research note released on Friday morning.

Separately, HC Wainwright upped their price objective on shares of Edap Tms from $16.00 to $19.00 and gave the stock a buy rating in a report on Monday, April 1st.

Edap Tms Stock Performance

Shares of EDAP opened at $7.26 on Friday. Edap Tms has a 1 year low of $3.60 and a 1 year high of $12.23. The company has a market cap of $269.38 million, a price-to-earnings ratio of -11.52 and a beta of 0.74. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.30 and a current ratio of 2.84. The firm has a fifty day moving average of $7.10 and a 200-day moving average of $6.27.

Edap Tms (NASDAQ:EDAP) last announced its quarterly earnings results on Wednesday, March 27th. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.13). Edap Tms had a negative net margin of 35.03% and a negative return on equity of 34.33%. The firm had revenue of $21.27 million for the quarter, compared to analyst estimates of $21.30 million. As a group, equities analysts anticipate that Edap Tms will post -0.31 earnings per share for the current year.

Institutional Investors Weigh In On Edap Tms

Several institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. bought a new stake in Edap Tms in the first quarter worth about $60,000. HighTower Advisors LLC bought a new stake in Edap Tms in the first quarter worth about $185,000. Envestnet Asset Management Inc. bought a new stake in Edap Tms in the second quarter worth about $80,000. Jane Street Group LLC bought a new stake in Edap Tms in the second quarter worth about $86,000. Finally, Royal Bank of Canada raised its position in Edap Tms by 136.4% in the third quarter. Royal Bank of Canada now owns 13,000 shares of the medical equipment provider’s stock worth $107,000 after acquiring an additional 7,500 shares in the last quarter. Institutional investors and hedge funds own 62.74% of the company’s stock.

Edap Tms Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST) segments.